ARQT logo

Arcutis Biotherapeutics (ARQT) Cash from operations

annual CFO:

-$112.16M+$134.90M(+54.60%)
December 31, 2024

Summary

  • As of today (May 24, 2025), ARQT annual cash flow from operations is -$112.16 million, with the most recent change of +$134.90 million (+54.60%) on December 31, 2024.
  • During the last 3 years, ARQT annual CFO has risen by +$62.47 million (+35.77%).
  • ARQT annual CFO is now -2871.07% below its all-time high of -$3.77 million, reached on December 31, 2017.

Performance

ARQT Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherARQTcash flow metrics

quarterly CFO:

-$30.38M-$29.63M(-3961.50%)
March 31, 2025

Summary

  • As of today (May 24, 2025), ARQT quarterly cash flow from operations is -$30.38 million, with the most recent change of -$29.63 million (-3961.50%) on March 31, 2025.
  • Over the past year, ARQT quarterly CFO has increased by +$1.22 million (+3.87%).
  • ARQT quarterly CFO is now -3961.50% below its all-time high of -$748.00 thousand, reached on December 31, 2024.

Performance

ARQT quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherARQTcash flow metrics

TTM CFO:

-$110.94M+$1.22M(+1.09%)
March 31, 2025

Summary

  • As of today (May 24, 2025), ARQT TTM cash flow from operations is -$110.94 million, with the most recent change of +$1.22 million (+1.09%) on March 31, 2025.
  • Over the past year, ARQT TTM CFO has increased by +$87.38 million (+44.06%).
  • ARQT TTM CFO is now -1468.21% below its all-time high of -$7.07 million, reached on March 31, 2019.

Performance

ARQT TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherARQTcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ARQT Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+54.6%+3.9%+44.1%
3 y3 years+35.8%+46.7%+40.2%
5 y5 years-161.8%-44.6%-95.4%

ARQT Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+56.5%-3961.5%+62.2%at high+61.2%
5 y5-year-161.8%+56.5%-3961.5%+62.2%-95.4%+61.2%
alltimeall time-2871.1%+56.5%-3961.5%+62.2%-1468.2%+61.2%

ARQT Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
-$30.38M(+3961.5%)
-$110.94M(-1.1%)
Dec 2024
-$112.16M(-54.6%)
-$748.00K(-97.8%)
-$112.16M(-33.1%)
Sep 2024
-
-$34.69M(-23.1%)
-$167.65M(-5.3%)
Jun 2024
-
-$45.12M(+42.8%)
-$176.95M(-10.8%)
Mar 2024
-
-$31.60M(-43.8%)
-$198.32M(-19.7%)
Dec 2023
-$247.06M(-4.1%)
-$56.24M(+27.9%)
-$247.06M(-5.7%)
Sep 2023
-
-$43.98M(-33.8%)
-$261.88M(-8.3%)
Jun 2023
-
-$66.48M(-17.2%)
-$285.59M(+1.6%)
Mar 2023
-
-$80.34M(+13.1%)
-$281.08M(+9.1%)
Dec 2022
-$257.71M(+47.6%)
-$71.06M(+5.0%)
-$257.71M(+8.1%)
Sep 2022
-
-$67.69M(+9.2%)
-$238.36M(+12.7%)
Jun 2022
-
-$61.98M(+8.8%)
-$211.55M(+14.1%)
Mar 2022
-
-$56.98M(+10.2%)
-$185.40M(+6.2%)
DateAnnualQuarterlyTTM
Dec 2021
-$174.63M(+54.5%)
-$51.71M(+26.5%)
-$174.63M(+12.3%)
Sep 2021
-
-$40.88M(+14.1%)
-$155.49M(+4.9%)
Jun 2021
-
-$35.83M(-22.4%)
-$148.30M(+7.3%)
Mar 2021
-
-$46.20M(+41.9%)
-$138.23M(+22.3%)
Dec 2020
-$113.03M(+163.9%)
-$32.57M(-3.3%)
-$113.03M(+16.2%)
Sep 2020
-
-$33.69M(+30.8%)
-$97.26M(+30.9%)
Jun 2020
-
-$25.76M(+22.6%)
-$74.29M(+30.9%)
Mar 2020
-
-$21.01M(+25.1%)
-$56.77M(+32.5%)
Dec 2019
-$42.84M(+204.1%)
-$16.80M(+56.7%)
-$42.84M(+64.5%)
Sep 2019
-
-$10.72M(+30.1%)
-$26.04M(+70.0%)
Jun 2019
-
-$8.24M(+16.5%)
-$15.32M(+116.5%)
Mar 2019
-
-$7.07M
-$7.07M
Dec 2018
-$14.09M(+273.1%)
-
-
Dec 2017
-$3.77M
-
-

FAQ

  • What is Arcutis Biotherapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Arcutis Biotherapeutics?
  • What is Arcutis Biotherapeutics annual CFO year-on-year change?
  • What is Arcutis Biotherapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Arcutis Biotherapeutics?
  • What is Arcutis Biotherapeutics quarterly CFO year-on-year change?
  • What is Arcutis Biotherapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Arcutis Biotherapeutics?
  • What is Arcutis Biotherapeutics TTM CFO year-on-year change?

What is Arcutis Biotherapeutics annual cash flow from operations?

The current annual CFO of ARQT is -$112.16M

What is the all time high annual CFO for Arcutis Biotherapeutics?

Arcutis Biotherapeutics all-time high annual cash flow from operations is -$3.77M

What is Arcutis Biotherapeutics annual CFO year-on-year change?

Over the past year, ARQT annual cash flow from operations has changed by +$134.90M (+54.60%)

What is Arcutis Biotherapeutics quarterly cash flow from operations?

The current quarterly CFO of ARQT is -$30.38M

What is the all time high quarterly CFO for Arcutis Biotherapeutics?

Arcutis Biotherapeutics all-time high quarterly cash flow from operations is -$748.00K

What is Arcutis Biotherapeutics quarterly CFO year-on-year change?

Over the past year, ARQT quarterly cash flow from operations has changed by +$1.22M (+3.87%)

What is Arcutis Biotherapeutics TTM cash flow from operations?

The current TTM CFO of ARQT is -$110.94M

What is the all time high TTM CFO for Arcutis Biotherapeutics?

Arcutis Biotherapeutics all-time high TTM cash flow from operations is -$7.07M

What is Arcutis Biotherapeutics TTM CFO year-on-year change?

Over the past year, ARQT TTM cash flow from operations has changed by +$87.38M (+44.06%)
On this page